Skip to main content

Table 2 Summary of the stability control and of the pre-treatment patients quality assurance results for RapidArc and IMRT treatments.

From: Commissioning and early experience with a new-generation low-energy linear accelerator with advanced delivery and imaging functionalities

   Unique Clinac iX
GAI [%] constancy on a pre-treatment QA case (1 year data with a periodicity of 2 weeks) RapidArc case 98.5 ± 1.1 [96.7, 99.6] 99.0 ± 0.3 [98.3, 99.4]
  IMRT case 99.4 ± 0.1 [99.2, 99.2] 99.0 ± 0.4 [98.2, 99.3]
Clinical pre-treatment RapidArc QA GAI [%] 97.3 ± 1.6 [92.4, 99.9] 97.4 ± 1.8 [91.5, 99.9]
  Number of arcs (plans) 348 (192) [12 months] 1186 (797) [31 months]
  1. Beside UNIQUE summary, a comparison with similar results from the Clinac iX operational at the institute is shown. Data are expressed as Gamma Agreement Index GAI with Distance to Agreement and Dose Difference thresholds set to 3 mm and 3%. Measurements and calculations were performed according to the GLAaS method by means of portal dosimetry.